Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome

Genomics

Volumn 93, Issue 3, 2009, Pages 221-226

  Yoshida, Tetsuro ^a   Kato, Kimihiko ^b   Fujimaki, Tetsuo ^b   Yokoi, Kiyoshi ^b   Oguri, Mitsutoshi ^c   Watanabe, Sachiro ^d   Metoki, Norifumi ^e   Yoshida, Hidemi ^f   Satoh, Kei ^f   Aoyagi, Yukitoshi ^g   Nishigaki, Yutaka ^g   Tanaka, Masashi ^g   Nozawa, Yoshinori ^h   Yamada, Yoshiji ⁱ  

^a Inabe General Hospital   (Japan)

^b GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^e Hirosaki Stroke Center   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

^g TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^h GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

ⁱ MIE UNIVERSITY   (Japan)

Author keywords

Apolipoprotein E; Chronic kidney disease; Genetic; Genetics; Metabolic syndrome; Polymorphism

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN E; CARBOXYPEPTIDASE B; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PREVALENCE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 59849109054     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2008.11.001     Document Type: Article

References (46)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 suppl 1 (2002) S1-S266
2. Weiner D.E., et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 15 (2004) 1307-1315
3. Jafar T.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 139 (2003) 244-252
4. Grundy S.M., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
5. Tanaka H., Shiohira Y., Uezu Y., Higa A., and Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 69 (2006) 369-374
6. Chen J., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 140 (2004) 167-174
7. Ninomiya T., et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am. J. Kidney Dis. 48 (2006) 383-391
8. Lakka H.M., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
9. McNeill A.M., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 (2005) 385-390
10. Boden-Albala B., et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 39 (2008) 30-35
11. Najarian R.M., et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch. Intern. Med. 166 (2006) 106-111
12. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
13. Beisiegel U., et al. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 341 (1989) 162-164
14. Ehnholm C., Lukka M., Kuusi T., Nikkilä E., and Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J. Lipid Res. 27 (1986) 227-235
15. Sing C.F., and Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37 (1985) 268-285
16. Xhignesse M., Lussier-Cacan S., Sing C.F., Kessling A.M., and Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler. Thromb. 11 (1991) 1100-1110
17. Wilson P.W., et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272 (1994) 1666-1671
18. van Bockxmeer F.M., and Mamotte C.D. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 340 (1992) 879-880
19. Lahoz C., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154 (2001) 529-537
20. Song Y., Stampfer M.J., and Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141 (2004) 137-147
21. Hsu C.C., et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 293 (2005) 2892-2899
22. Kimura H., et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am. J. Kidney Dis. 31 (1998) 666-673
23. Oda H., Yorioka N., Ueda C., Kushihata S., and Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int. 56 suppl 71 (1999) S25-S27
24. Lambert J.C., et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum. Mol. Genet. 9 (2000) 57-61
25. Hirashiki A., et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 42 (2003) 1429-1437
26. Kasiske B.L. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int. 31 (1987) 1153-1159
27. Keane W.F., Kasiske B.L., and O ' Donnell M.P. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am. J. Nephrol. 8 (1988) 261-271
28. Harada T. A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (ABCA1) alters high density lipoprotein cholesterol level in Japanese population. Atherosclerosis 169 (2003) 105-112
29. Hodoǧlugil U., Williamson D.W., Huang Y., and Mahley R.W. Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. Atherosclerosis 183 (2005) 199-212
30. Suwazono Y., et al. G-protein beta 3 subunit polymorphism C1429T and low-density lipoprotein receptor-related protein 5 polymorphism A1330V are risk factors for hypercholesterolemia in Japanese males - a prospective study over 5 years. Metabolism 55 (2006) 751-757
31. Lee C.R., et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin. Pharmacol. Ther. 83 (2008) 52-60
32. Juhan-Vague I., et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 867-873
33. Shiffman D., et al. Identification of four gene variants associated with myocardial infarction. Am. J. Hum. Genet. 77 (2005) 596-605
34. Hsu C.C., et al. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 17 (2006) 504-512
35. Coll E., Campos B., González-Núñez D., Botey A., and Poch E. Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J. Nephrol. 16 (2003) 357-364
36. Thibaudin D., et al. TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy. Kidney Int. 71 (2007) 431-437
37. Buraczynska M., Mierzicki P., Buraczynska K., Dragan M., and Ksiazek A. Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease. Mol. Diagn. Ther. 11 (2007) 257-263
38. Yamada Y., Ichihara S., Izawa H., Tanaka M., and Yokota M. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol. Genet. Metab. 81 (2004) 282-290
39. Sattar N., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
40. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
41. Kanazawa M., et al. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac. J. Clin. Nutr. 11 suppl 8 (2002) S732-S737
42. Imai E., et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens. Res. 31 (2008) 1101-1107
43. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351 (2004) 1296-1305
44. Imai E., et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens. Res. 31 (2008) 433-441
45. Itoh Y., et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 57 (2005) 717-729
46. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. Ser. B. 57 (1995) 289-300